|
Q BioMed Bolsters Commercialization of Strontium89 with EVERSANA Partnership
|
Nov 08, 2021 |
|
Q BioMed Inc. Provides Shareholder Update
|
Oct 25, 2021 |
|
Q BioMed Inc. Provides Update on Strontium89 Commercial Roll Out
|
Sep 28, 2021 |
|
Q BioMed Inc. Updates on Covid-19 Therapeutic Development and Clinical Trials - MAN-19 therapeutic program heading to clinical trial in early 2022
|
Sep 22, 2021 |
|
Q BioMed Inc. Chemotherapeutic Uttroside B, Receives Notice of Allowance for Patent in South Korea and Shows Promising Results in Initial Pre-Clinical Testing
|
Aug 24, 2021 |
|
Q BioMed Signs Distribution Agreement with isoSolutions for the Sales of Strontium89 in Canada
|
Aug 10, 2021 |
|
Q BioMed Signs License Agreement with Clionix for the Distribution and Sales of Strontium89 in Europe and Middle East
|
Jul 12, 2021 |
|
Q BioMed Engages Contract Sales Force with Deep VA and Oncology Experience
|
May 20, 2021 |
|
Q BioMed Insider to Invest up to $30M in the Company
|
May 11, 2021 |
|
Q BioMed Updates Shareholders
|
Apr 27, 2021 |
|
Q BioMed Awarded Federal Supply Contract for Strontium89 with U.S. Department of Defense and Veterans Affairs
|
Mar 02, 2021 |
|
Q BioMed Expands Strontium89 Reach Through Agreement with UroGPO, the Largest Group Purchasing Organization for Independent Urology Clinics in the US
|
Feb 01, 2021 |
|
Q BioMed’s Uttroside-B Receives U.S. FDA Orphan Drug Designation in the Treatment of Liver Cancer
|
Jan 27, 2021 |
|
Q BioMed’s Uttroside-B Receives Additional Patent Coverage in Canada and Japan
|
Jan 26, 2021 |
|
Strontium89 Now Reimbursed in Hospital and Outpatient Settings for Metastatic Bone Pain Treatment
|
Jan 07, 2021 |
